Cadrenal Therapeutics, Inc. (CVKD) intrinsic value & 10-year financials
Cadrenal Therapeutics, Inc. (CVKD) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.09
- Market cap
- $2.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -83.5%
- Free cash flow (FY2025)
- -$12.6M
CVKD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$13.2M | -$6.64 | -$12.6M | — | -260.1% |
| FY2024 | — | -$10.7M | -$8.73 | -$7.4M | — | -140.8% |
| FY2023 | — | -$8.4M | -$0.62 | -$3.5M | — | 150.2% |
| FY2022 | — | — | — | — | — | — |
| FY2008 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cadrenal Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cadrenal Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -47.3% ROIC.
Cadrenal Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Cadrenal Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.